[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Fiorella R, Di Nicola V, Fiorella ML, Spinelli DA, Coppola F, Luperto P, Madami L: Major salivary gland diseases. Multicentre study. Acta Otorhinolaryngol Ital; 2005 Jun;25(3):182-90
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This multicentre study involved 28 Italian ORL Centres responding to a questionnaire sent by us which allowed recruitment of a high large number of cases of parotid neoplasms observed over a 10-year period.
  • Adenoid-cystic carcinoma was observed in 15.3% and < or = 10% for all the other most frequent histological malignant neoplasms.
  • Diagnostic work-up included echotomography and fine-needle aspiration biopsy, less used imaging techniques were computed tomography, magnetic resonance imaging, Sialo-computed tomography.
  • Surgical treatment of benign tumours consisted, in 50% of cases, in superficial paroditectomy and in approximately 30% of total paroditectomy.
  • Enucleoresection was limited to approximately 15% of neoplasms, enucleation to <10% of cases with only 2% of pleomorph adenoma due to the well-known anatomo-pathological characteristics which may lead to relapse.
  • For malignant neoplasms, total parotidectomy was performed in approximately 50% of cases, while in the remaining 50% an almost equal rate of superficial parotidectomy was carried out and enlarged parotidectomy, with or without sacrificing the facial nerve, which was rebuilt in 60% of cases.
  • The lateral neck dissection most frequently carried out was of functional type in 54% and selective type in 46% with removal of levels I-III and II-IV in approximately 60% of cases.
  • Post-operative-complementary radiotherapy was very frequently performed instead of chemotherapy.
  • Oncological results obtained were compared with those reported in the literature: in fact for all benign neoplasms relapse ratings are about 5%, while for malignant tumours the worst prognosis was in squamous cell carcinoma with median of 37.7 on survival and metastasis rate of 16.5%.
  • [MeSH-major] Salivary Gland Neoplasms
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Australas Radiol. 1999 Nov;43(4):520-2 [10901971.001]
  • [Cites] Laryngoscope. 2001 Nov;111(11 Pt 1):1984-8 [11801983.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):729-38 [11849796.001]
  • [Cites] Atlas Oral Maxillofac Surg Clin North Am. 1998 Mar;6(1):1-28 [11905347.001]
  • [Cites] J Laryngol Otol. 2002 Apr;116(4):285-7 [11945190.001]
  • [Cites] Acta Otorhinolaryngol Ital. 2002 Apr;22(2):80-5 [12068476.001]
  • [Cites] J Laryngol Otol. 2002 May;116(5):359-62 [12080993.001]
  • [Cites] Laryngoscope. 2002 Dec;112(12):2141-54 [12461331.001]
  • [Cites] Mund Kiefer Gesichtschir. 2003 Mar;7(2):94-101 [12664254.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):931-40 [12820326.001]
  • [Cites] Am J Surg. 2003 Jul;186(1):57-62 [12842751.001]
  • [Cites] Laryngoscope. 2003 Aug;113(8):1299-303 [12897549.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):257-9 [12903612.001]
  • [Cites] J Laryngol Otol. 2003 Aug;117(8):624-9 [12956917.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):929-33 [12975263.001]
  • [Cites] World J Surg. 2003 Jul;27(7):863-7 [14509520.001]
  • [Cites] Head Neck. 2003 Nov;25(11):946-52 [14603455.001]
  • [Cites] Chir Ital. 2003 Nov-Dec;55(6):857-64 [14725226.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2004 Mar;261(3):143-6 [12883818.001]
  • [Cites] Otolaryngol Pol. 2004;58(1):109-14 [15101269.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Jan;13(1):113-27 [15062365.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jun;130(6):773-8 [15210562.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2005 Feb;23(1):53-6 [15804023.001]
  • [ErratumIn] Acta Otorhinolaryngol Ital. 2005 Oct;25(5):following 337
  • (PMID = 16450775.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2639866
  •  go-up   go-down


2. Prigent M, Teissier N, Peuchmaur M, El Maleh-Berges M, Philippe-Chomette P, Cardin P, Orbach D: Sialoblastoma of salivary glands in children: chemotherapy should be discussed as an alternative to mutilating surgery. Int J Pediatr Otorhinolaryngol; 2010 Aug;74(8):942-5
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sialoblastoma of salivary glands in children: chemotherapy should be discussed as an alternative to mutilating surgery.
  • Sialoblastoma is a very rare congenital salivary gland tumor.
  • No consensus has been reached concerning the treatment of this tumor due to its rarity.
  • The treatment of reference is surgery, which can be mutilating, in the case of a locally invasive tumor.
  • The treatment of metastatic disease is also controversial.
  • The first cytological diagnosis was that of pleomorphic adenoma.
  • Due to local progression, superficial parotidectomy was performed at the age of 3.5 years and revealed a diagnosis of sialoblastoma.
  • Six months later, local recurrence and lung metastasis were treated by neoadjuvant chemotherapy with a very good partial response on the local recurrence and the lung metastasis, allowing complete parotidectomy with sacrifice of the facial nerve.
  • Bilateral lung biopsies after adjuvant chemotherapy showed total necrosis.
  • This case and a review of the literature confirm the very good chemosensitivity of this tumor and argue in favor of neoadjuvant chemotherapy for locally invasive tumors rather than extensive mutilating surgery.
  • [MeSH-major] Adenoma, Pleomorphic / therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / drug therapy. Salivary Gland Neoplasms / therapy
  • [MeSH-minor] Biopsy, Needle. Child. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Neoplasm Staging. Rare Diseases. Risk Assessment. Salivary Glands / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright (c) 2010. Published by Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20554035.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  •  go-up   go-down


3. Bouyon A, Hans S, Durdux C, Housset M: [Postoperative treatment of malignant tumors of the parotid gland: radiotherapy, concomitant chemotherapy and radiation therapy?]. Cancer Radiother; 2007 Dec;11(8):465-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Postoperative treatment of malignant tumors of the parotid gland: radiotherapy, concomitant chemotherapy and radiation therapy?].
  • The low incidence, the wide histological spectrum and the natural, sometimes slow, evolution of malignant parotid gland tumours do not allow to easily establish the impact of their treatments.
  • We present here the therapeutic highlights of parotid cancers: surgery, with the particular concern of facial nerve preservation; and adjuvant treatment essentially based on radiotherapy.
  • This review focused on adjuvant care explores the indications and the technical aspects of radiation, as well as the role of concurrent chemotherapy.
  • [MeSH-major] Parotid Neoplasms / radiotherapy. Parotid Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy / methods. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17888707.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. BenJelloun H, Jouhadi H, Maazouzi A, Benchakroun N, Acharki A, Tawfiq N, Sahraoui S, Benider A: [Rhabdomyosarcoma of the salivary glands. Report of 3 cases]. Cancer Radiother; 2005 Sep;9(5):316-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumefaction of the parotid region and facial paralysis were the principle clinical symptoms.
  • The third patient had a locally advanced tumour and received chemotherapy followed by radiotherapy.
  • Treatments include surgery and radiotherapy.
  • The role of chemotherapy remains to be discussed.
  • [MeSH-major] Parotid Neoplasms / diagnosis. Rhabdomyosarcoma, Alveolar / diagnosis
  • [MeSH-minor] Adolescent. Aged. Chemotherapy, Adjuvant. Child. Facial Nerve / pathology. Facial Paralysis / etiology. Fatal Outcome. Female. Humans. Neoplasm Invasiveness. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15953749.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Leach BC, Kulbersh JS, Day TA, Cook J: Cranial neuropathy as a presenting sign of recurrent aggressive skin cancer. Dermatol Surg; 2008 Apr;34(4):483-97
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial neuropathy as a presenting sign of recurrent aggressive skin cancer.
  • OBJECTIVE: The purpose of this study was to identify and characterize recurrent skin cancers of the head and neck presenting with cranial neuropathies and to review the presentation and the management for this rare subset of cutaneous neoplasms.
  • MATERIALS AND METHODS: A retrospective review was performed for all patients with previous related cutaneous neoplasms presenting with cranial neuropathies referred to a single academic tertiary-care head and neck tumor program from 1999 to 2007.
  • Six cases of head and neck carcinoma with demonstrable cranial neuropathy were identified and analyzed by clinical history, radiographic and surgical findings, and treatment and survival data.
  • RESULTS: Cranial neuropathy was the presenting symptom of recurrent disease in all six patients.
  • Four presented with multiple cranial neuropathies.
  • All exhibited neuropathy of the trigeminal nerve (cranial nerve V).
  • The tumors involved were squamous cell carcinoma (4) and melanoma (2).
  • All patients were multiply symptomatic, presenting with a mean of three neurologic symptoms, including facial numbness (5), facial paralysis or weakness (3), facial pain (3), diplopia (3), paresthesia (3), hearing loss (1), or formication (2).
  • Symptoms were present for an average of 7 months prior to diagnosis of perineural recurrence.
  • Cranial nerve involvement was confirmed in all patients by magnetic resonance imaging, and five patients manifested histologic evidence of perineural tumor infiltration.
  • Treatment consisted of various combinations of surgery, radiation, and chemotherapy for five patients, and one patient declined any intervention.
  • CONCLUSION: Cranial neuropathy is a rare presentation of recurrent cutaneous neoplasms of the head and neck.
  • Given this infrequent occurrence and shared features of presentation, these highly morbid tumors are often mistakenly diagnosed as Bell's palsy or trigeminal neuralgia.
  • Our findings corroborate previous reports of diagnostic delay, increased tumor burden, and worsened morbidity and mortality associated with such cutaneous malignancies.
  • The critical utility of radiologic imaging for staging and tumor delineation are also supported by our institutional data.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cranial Nerve Diseases / etiology. Head and Neck Neoplasms / pathology. Melanoma / pathology. Neoplasm Recurrence, Local / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Cohort Studies. Humans. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248467.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Minovi A, Basten O, Hunter B, Draf W, Bockmühl U: Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review. Head Neck; 2007 May;29(5):439-45
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review.
  • BACKGROUND: This study analyzes the management and outcomes of a series of 10 malignant peripheral nerve sheath tumors (MPNST) of the head and neck.
  • METHODS: From 1984 to 2004, 10 patients underwent surgical treatment of a MPNST.
  • RESULTS: Eight tumors were located at the lateral skull base; 2 involved the vagus nerve in isolation.
  • Seventy percent of the tumors could be resected completely.
  • Negative prognostic indicators were advanced tumor stage, early recurrence, and presumably also the presence of von Recklinghausen's disease.
  • CONCLUSIONS: Although rare, MPNST is one of the most aggressive tumors in the head and neck area.
  • Complete tumor removal is the mainstay of treatment and most important prognostic factor of MPNST.
  • The role of adjuvant chemotherapy remains controversial.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / mortality. Nerve Sheath Neoplasms / mortality. Nerve Sheath Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley Periodicals, Inc.
  • (PMID = 17163467.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


7. Selesnick SH, Burt BM: Regional spread of nonneurogenic tumors to the skull base via the facial nerve. Otol Neurotol; 2003 Mar;24(2):326-33
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional spread of nonneurogenic tumors to the skull base via the facial nerve.
  • OBJECTIVE: This study examined the clinical and pathologic features of regional spread of nonneurogenic neoplastic disease to the intratemporal segments of the facial nerve.
  • PATIENTS: Six patients with neoplastic disease of nonneurogenic origin involving segments of the facial nerve within the temporal bone.
  • Five patients received adjuvant radiation, and two received adjuvant radiation and chemotherapy.
  • MAIN OUTCOME MEASURES: Histopathology, site of primary tumor, intratemporal location of regional spread along the facial nerve, degree of facial paralysis, and presence of residual disease.
  • In addition, one case of benign pleomorphic adenoma of the parotid gland that circumferentially involved an intratemporal segment of the facial nerve was reported.
  • Facial paralysis was present in five of six (83%) of cases.
  • Four patients had unresectable malignant disease, and two died despite multimodality therapy.
  • CONCLUSIONS: The facial nerve provides a route for the spread of neoplastic disease into the temporal bone, and perineural invasion is an important mechanism of invasion and motility of malignant disease.
  • Nonneurogenic intratemporal tumors of the facial nerve are a rare but significant cause of facial paralysis.
  • [MeSH-major] Carcinoma / pathology. Cranial Nerve Neoplasms / pathology. Facial Nerve / pathology. Parotid Neoplasms / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Child. Female. Gadolinium. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness / pathology. Radiopharmaceuticals. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621352.001).
  • [ISSN] 1531-7129
  • [Journal-full-title] Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
  • [ISO-abbreviation] Otol. Neurotol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


8. Ruffatti S, Zanchin G, Maggioni F: A case of intractable facial pain secondary to metastatic lung cancer. Neurol Sci; 2008 Apr;29(2):117-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of intractable facial pain secondary to metastatic lung cancer.
  • Persistent idiopathic facial pain, once called atypical facial pain, rarely anticipates the detection of a lung carcinoma.
  • Thirty-six cases of intractable facial pain secondary to lung neoplasm are described in the literature.
  • The onset of facial pain usually precedes the onset of symptoms and signs due to lung cancer by several months and therefore it should be considered, when present, as a possible marker for an early diagnosis of tumour.
  • We report a case of intractable facial pain associated with metastatic lung cancer in a non-smoker.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Facial Pain / etiology. Facial Pain / pathology. Lung Neoplasms / pathology. Pain, Intractable / etiology. Pain, Intractable / pathology
  • [MeSH-minor] Aged. Drug Therapy. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Radiotherapy. Tomography, X-Ray Computed. Trigeminal Nerve Diseases / etiology. Trigeminal Nerve Diseases / pathology. Trigeminal Nerve Diseases / physiopathology. Trigeminal Nuclei / pathology. Trigeminal Nuclei / physiopathology


9. Kurian S, Ertan E, Ducatman B, Crowell EB, Rassekh C: Esthesioneuroblastoma in Maffucci's syndrome. Skeletal Radiol; 2004 Oct;33(10):609-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 33-year-old man with Maffucci's syndrome who presented with a several month history of nasal congestion, facial pain, and diminished vision in his left eye.
  • Radiological studies showed a large soft tissue mass centered in the sinonasal area, extending bilaterally into maxillary sinuses and orbits with compression of left optic nerve.
  • Chemotherapy resulted in initial improvement, but the tumor recurred and did not respond to further treatment, resulting in his death.
  • Sarcomatous tumors are reported in Maffucci's syndrome, but this is a rare case of a neuroendocrine tumor in a patient with Maffucci's syndrome.
  • [MeSH-major] Enchondromatosis / complications. Esthesioneuroblastoma, Olfactory / diagnosis. Nasal Cavity / pathology. Nose Neoplasms / diagnosis
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Male. Maxillary Sinus Neoplasms / diagnosis. Neoplasm Recurrence, Local / pathology. Orbital Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Am J Clin Oncol. 1990 Apr;13(2):139-43 [2180272.001]
  • [Cites] Arch Otolaryngol. 1979 Jul;105(7):427-30 [454301.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2426-8 [2720589.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Jun;15(6):1169-77 [8073990.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Dermatol Clin. 1995 Jan;13(1):73-8 [7712654.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Jan;123(1):34-40 [9006501.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 15221218.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Harish K: Management of primary malignant epithelial parotid tumors. Surg Oncol; 2004 Jul;13(1):7-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary malignant epithelial parotid tumors.
  • These tumors carry a prolonged risk of recurrence and metastasis.
  • Controversies surrounding pre-treatment evaluation by imaging and fine needle aspiration, utility of operative frozen section are partly resolved.
  • Though surgery remains the mainstay of treatment, radiation is being recognized as a useful adjuvant.
  • Facial nerve preservation is one of the important goals at surgery.
  • The role of chemotherapy is still investigational.
  • The prognosis and necessity of elective neck treatment are mainly guided by the tumor grade and stage.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / therapy. Parotid Neoplasms / therapy
  • [MeSH-minor] Humans. Lymph Node Excision. Neoplasm Staging. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15145029.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 81
  •  go-up   go-down


11. Wanyura H, Uliasz M, Kaminski A, Samolczyk-Wanyura D, Smolarz-Wojnowska A: Diagnostic difficulties and treatment of non-Hodgkin lymphoma of the orbit. J Craniomaxillofac Surg; 2007 Jan;35(1):39-47
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic difficulties and treatment of non-Hodgkin lymphoma of the orbit.
  • BACKGROUND: There are problems connected with the diagnosis of non-Hodgkin lymphomas of the orbit, before deciding on the correct treatment.
  • Histological diagnosis of the tumours was made from the surgical specimens.
  • All patients had received chemotherapy.
  • The last patient, in whom the lymphoma was diagnosed at the age of 70 years, died 4 years after the procedure without relapse due to cardiovascular and respiratory insufficiency.
  • CONCLUSIONS: Although the treatment of choice of NHL is chemotherapy, it is felt necessary to remove the whole or possibly the major part of the tumour in case of retrobulbar location when the histological subtype is unknown prior to surgery.
  • However, the optic nerve should always been left intact, even when such tumour encircles this cranial nerve.
  • Only sufficient biopsy material allows determination of the lymphoma subtype and selection of appropriate chemotherapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Diagnosis, Differential. Disease-Free Survival. Female. Humans. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / surgery. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / surgery. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / surgery. Male. Middle Aged. Neoplasm Staging. Patient Care Planning. Remission Induction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267230.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


12. Stannard C, Sealy R, Hering E, Hough J, Knowles R, Lecuona K, Reddi VB: Postenucleation orbits in retinoblastoma: treatment with 125I brachytherapy. Int J Radiat Oncol Biol Phys; 2002 Dec 1;54(5):1446-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postenucleation orbits in retinoblastoma: treatment with 125I brachytherapy.
  • PURPOSE: Children with retinoblastoma that extends into or through the choroid, sclera, or optic nerve are at risk of developing orbital disease, as well as metastases.
  • Previously, these enucleated orbits were treated with external beam radiotherapy in addition to chemotherapy.
  • 125I brachytherapy for tumors in and around the eye was pioneered by Sealy in Cape Town, South Africa, in 1974.
  • In 1983, he developed a technique to irradiate the contents of the orbit while limiting the dose to the bony orbit and eyelids.
  • A seventh unscreened tube was placed in the center, and a metal disc with 125I seeds on its posterior surface was secured beneath the eyelids.
  • Thirty-six were treated prophylactically and 21, with tumor at the resection line of the nerve, extrascleral tumor, or metastases, were treated therapeutically.
  • They received a median dose of 34 Gy in 70 h; 30 also received chemotherapy.
  • Children with tumor at the resection line of the nerve also received treatment to the craniospinal axis.
  • Eight of the 13 patients with microscopic extraocular tumor survived a median of 29 months (range 5-156).
  • None of the 8 patients presenting with orbital tumor or metastases survived.
  • No orbital recurrences developed in any of the patients.
  • CONCLUSION: Orbital brachytherapy is an effective method of irradiating the orbit to prevent recurrent tumor, the treatment time is short, and the cosmesis is much more acceptable than with other forms of irradiation.
  • No facial atrophy or second nonocular tumors have occurred.
  • [MeSH-major] Brachytherapy / instrumentation. Brachytherapy / methods. Eye Neoplasms / radiotherapy. Iodine Radioisotopes / therapeutic use. Retinoblastoma / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Dose-Response Relationship, Radiation. Follow-Up Studies. Hot Temperature. Humans. Infant. Neoplasm Metastasis. Radiometry. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12459368.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes
  •  go-up   go-down


13. Charabi S, Balle V, Charabi B, Nielsen P, Thomsen J: Surgical outcome in malignant parotid tumours. Acta Otolaryngol Suppl; 2000;543:251-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four therapeutic modalities were applied: surgery only, surgery + radiation, surgery + chemotherapy, and surgery + chemotherapy + radiation.
  • Normal or nearly normal facial nerve function (HB1&2) was noted at last follow-up in 60%.
  • No significant difference was observed in 5-year crude survival or in the post-operative facial nerve function between the radically operated patients (n = 38) and patients with residual tumour (p = 0.27, Log-rank test), (p = 0.48, chi 2 test).
  • [MeSH-major] Parotid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Catchment Area (Health). Combined Modality Therapy. Denmark / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10909035.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] NORWAY
  •  go-up   go-down


14. Pereira LS, Green AJ, Hwang TN, McCulley TJ: Suprasellar germinoma and late perioptic seeding. Eur J Ophthalmol; 2008 Jan-Feb;18(1):159-61
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report an unusual case of optic nerve seeding 12 years following treatment of a suprasellar germinoma.
  • The tumor had shown complete radiographic regression without neurologic sequelae.
  • Pertinent findings on current examination included right eye visual acuity of 20/150, right relative afferent papillary defect, and optic nerve pallor in the right eye.
  • In addition, partial left facial paralysis was noted.
  • Magnetic resonance imaging demonstrated abnormal enhancement and thickening of both optic nerves and along the course of the left V and VII cranial nerves.
  • Following two cycles of chemotherapy (VIP-etoposide, ifosfamide, and cisplatin), visual acuity returned to 20/20 bilaterally, with corresponding radiographic improvement and normal cerebrospinal fluid cytology.
  • CONCLUSIONS: Perioptic subarachnoid seeding may occur over a decade after presumed successful treatment of germinomas, suggesting the importance of lifelong observation.
  • [MeSH-major] Brain Neoplasms / pathology. Germinoma / secondary. Neoplasm Seeding. Optic Nerve Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chorionic Gonadotropin, beta Subunit, Human / blood. Female. Humans. Magnetic Resonance Imaging. Visual Acuity. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Germinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203106.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


15. Viswanatha B: Embryonal rhabdomyosarcoma of the temporal bone. Ear Nose Throat J; 2007 Apr;86(4):218, 220-2
Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common soft-tissue sarcoma in infants and children is rhabdomyosarcoma.
  • Multimodality therapy--surgery, multiagent chemotherapy, and radiotherapy-yields sufficiently good results.
  • The author reports a case of embryonal rhabdomyosarcoma of the temporal bone with cranial nerve palsies and extension into the parapharyngeal space in a 4-year-old boy.
  • Despite surgery and chemotherapy, the patient died of his disease within 3 months of presentation.
  • [MeSH-major] Ear Canal. Ear Neoplasms / diagnosis. Ear, Middle. Facial Paralysis / etiology. Mastoid. Ophthalmoplegia / etiology. Rhabdomyosarcoma, Embryonal / diagnosis. Skull Neoplasms / diagnosis. Temporal Bone
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Palliative Care. Pharyngeal Neoplasms / diagnosis. Pharyngeal Neoplasms / pathology. Pharyngeal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17500393.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Rittinger O, Kranzinger M, Jones R, Jones N: Malignant astrocytoma arising 10 years after combined treatment of craniopharyngioma. J Pediatr Endocrinol Metab; 2003 Jan;16(1):97-101
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant astrocytoma arising 10 years after combined treatment of craniopharyngioma.
  • Craniopharyngioma is the third most common intracranial tumor in childhood.
  • Following surgery, virtually all patients present with hypopituitarism and are at considerable risk of tumor recurrence.
  • Secondary tumors, however, are rare, occurring usually 10 years after diagnosis and associated with poor prognosis.
  • After surgery he underwent conventional radiation therapy with a total tumor dose of 55 Gy, and had hormonal support with DDAVP, thyroxine, and a variable dose of hydrocortisone.
  • Growth velocity declined slowly in the first 4 years, but improved later on again without GH therapy despite abnormal provocative tests.
  • At the age of 15 years he developed peripheral facial nerve palsy due to a malignant astrocytoma (WHO grade III/IV).
  • Repeated conventional radiation therapy with an additional stereotactic boost and chemotherapy could not prevent the fatal outcome.
  • This observation may temper the use of radiosurgery in benign intracranial tumors.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Stem Neoplasms / diagnosis. Craniopharyngioma / radiotherapy. Craniopharyngioma / surgery. Neoplasms, Second Primary / diagnosis. Pituitary Neoplasms / radiotherapy. Pituitary Neoplasms / surgery
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Fatal Outcome. Hormones / blood. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Time Factors

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12585346.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hormones
  •  go-up   go-down


17. Chee G, Mok P, Sim R: Squamous cell carcinoma of the temporal bone: diagnosis, treatment and prognosis. Singapore Med J; 2000 Sep;41(9):441-6, 451
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the temporal bone: diagnosis, treatment and prognosis.
  • The development of an accepted staging system has not been forthcoming and this has inhibited the formation of an evidence-based therapeutic protocol.
  • Five patients had facial palsy which was a poor prognostic sign.
  • With combination treatment involving surgery, radiotherapy and chemotherapy, disease free survival achieved was 69% (9 of 13) over a mean follow-up period of 24.7 months.
  • One patient absconded treatment.
  • Patients with facial nerve involvement had a significantly poorer outcome (p = 0.035).
  • [MeSH-major] Carcinoma, Squamous Cell. Skull Neoplasms. Temporal Bone / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193117.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


18. Obaid MA, Yusuf A: Surgical management of epithelial parotid tumours. J Coll Physicians Surg Pak; 2004 Jul;14(7):394-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the clinicopathological presentation and treatment options in epithelial parotid tumours with emphasis on surgery.
  • Clinical presentation, preoperative investigations, operative procedure, histopathology report, postoperative complications and further management were recorded.
  • Commonest presentation was a painless lump over the parotid region (85%), pain (15%), facial palsy, and enlarged neck nodes.
  • Except for one child, rest of the 13 patients received postoperative radiotherapy and one patient of lymphoepithelioma received chemotherapy in addition.
  • Commonest postoperative complication was temporary facial weakness in 35% (18/52).
  • Permanent facial palsy occurred in 08 patients.
  • Facial nerve can be saved in total conservative parotidectomy for benign tumour in deep lobe and early malignant tumour.
  • [MeSH-major] Adenoma, Pleomorphic / surgery. Parotid Gland / surgery. Parotid Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy, Needle. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Glandular and Epithelial / mortality. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / surgery. Postoperative Complications. Risk Assessment. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15279739.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


19. Gosau M, Draenert FG, Müller S, Frerich B, Bürgers R, Reichert TE, Driemel O: Two modifications in the treatment of keratocystic odontogenic tumors (KCOT) and the use of Carnoy's solution (CS)--a retrospective study lasting between 2 and 10 years. Clin Oral Investig; 2010 Feb;14(1):27-34
Hazardous Substances Data Bank. CHLOROFORM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two modifications in the treatment of keratocystic odontogenic tumors (KCOT) and the use of Carnoy's solution (CS)--a retrospective study lasting between 2 and 10 years.
  • This retrospective study aimed at evaluating the recurrence rates of keratocystic odontogenic tumors (KCOTs) that were enucleated with and without the application of Carnoy's solution (CS).
  • Recurrence rates were investigated in correlation with the respective treatment method applied.
  • Additionally, any damage to the inferior alveolar nerve associated with treatment was analyzed.
  • Treatments consisted of enucleation with (38.9%) or without (61.1%) the application of CS.
  • No detrimental effects of CS on the mandibular nerve were detected.
  • The application of CS did not cause any damage to the mandibular nerve.
  • [MeSH-major] Acetic Acid / therapeutic use. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant / methods. Chloroform / therapeutic use. Ethanol / therapeutic use. Jaw Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control. Odontogenic Tumors / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Cautery / methods. Child. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Mandibular Nerve / drug effects. Middle Aged. Neovascularization, Pathologic / drug therapy. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. ACETIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Oral Investig. 2010 Dec;14(6):719-21 [20838833.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 May;32B(3):202-6 [8762878.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Jan;36(1):20-5 [17156974.001]
  • [Cites] J Oral Maxillofac Surg. 1985 Mar;43(3):177-82 [2579223.001]
  • [Cites] Hum Genet. 1997 Oct;100(5-6):497-502 [9341860.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Jun;52(6):599-606 [8189298.001]
  • [Cites] Br J Oral Maxillofac Surg. 1997 Feb;35(1):46-8 [9043004.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):323-31 [12076694.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):85-7 [8528259.001]
  • [Cites] J Can Dent Assoc. 2008 Mar;74(2):165-165h [18353202.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Nov;90(5):553-8 [11077375.001]
  • [Cites] Lancet. 1992 Mar 7;339(8793):581-2 [1347096.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Jun;62(6):651-5; discussion 655-6 [15170272.001]
  • [Cites] J Oral Maxillofac Surg. 1992 Jan;50(1):22-6 [1370082.001]
  • [Cites] J Oral Maxillofac Surg. 2005 May;63(5):635-9 [15883937.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1991 Sep;72(3):265-9 [1717918.001]
  • [Cites] Mund Kiefer Gesichtschir. 2007 Sep;11(4):221-31 [17641919.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Mar;64(3):379-83 [16487797.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Sep;52(9):960-3 [8064460.001]
  • [Cites] J Dent Res. 1999 Jul;78(7):1345-53 [10403462.001]
  • [Cites] Int J Oral Maxillofac Surg. 1988 Feb;17(1):25-8 [3127485.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Nov;63(11):1662-6 [16243184.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Sep;52(9):964-6 [8064461.001]
  • [Cites] J Oral Sci. 2007 Sep;49(3):229-35 [17928730.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006 Jan;101(1):5-9; discussion 10 [16360602.001]
  • [Cites] J Oral Maxillofac Surg. 2001 Jul;59(7):720-5; discussion 726-7 [11429726.001]
  • [Cites] Med Oral. 2001 Nov-Dec;6(5):350-7 [11694868.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Aug;94(2):151-6 [12221380.001]
  • [Cites] Dtsch Zahnarztl Z. 1991 Jan;46(1):80-3 [1725863.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Nov;94(5):543-53 [12424446.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Nov;86(5):573-7 [9830650.001]
  • [Cites] Oral Maxillofac Surg Clin North Am. 2003 Aug;15(3):317-24 [18088685.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Jul;86(1):42-7 [9690244.001]
  • [Cites] Int J Oral Maxillofac Surg. 2001 Feb;30(1):14-25 [11289615.001]
  • [Cites] Dtsch Z Mund Kiefer Gesichtschir. 1990 Sep-Oct;14(5):375-7 [2135243.001]
  • [Cites] J Maxillofac Surg. 1981 Nov;9(4):228-36 [6172530.001]
  • [Cites] J Oral Maxillofac Surg. 1984 Jan;42(1):10-9 [6199488.001]
  • [Cites] J Dent Res. 2000 Jun;79(6):1418-22 [10890722.001]
  • (PMID = 19294436.001).
  • [ISSN] 1436-3771
  • [Journal-full-title] Clinical oral investigations
  • [ISO-abbreviation] Clin Oral Investig
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carnoy's solution; 3K9958V90M / Ethanol; 7V31YC746X / Chloroform; Q40Q9N063P / Acetic Acid
  •  go-up   go-down


20. Goyal S, Puri T, Julka PK, Rath GK: Excellent response to letrozole in brain metastases from breast cancer. Acta Neurochir (Wien); 2008 Jun;150(6):613-4; discussion 614-5
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cranial radiotherapy improves survival by only a few months and the role of systemic therapy is marginal and largely unexplored.
  • We report a patient with recurrent carcinoma of breast presenting with multiple bilateral cervical nodes and brain metastases manifesting as a right hemiparesis and facial nerve palsy, who was treated with palliative whole brain irradiation and letrozole.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal / secondary. Neoplasms, Hormone-Dependent / secondary. Nitriles / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Combined Modality Therapy. Cranial Irradiation. Female. Humans. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Neurologic Examination. Palliative Care. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18458809.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


21. Landström FJ, Nilsson CO, Crafoord S, Reizenstein JA, Adamsson GB, Löfgren LA: Electroporation therapy of skin cancer in the head and neck area. Dermatol Surg; 2010 Aug;36(8):1245-50
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electroporation therapy of skin cancer in the head and neck area.
  • BACKGROUND: Electroporation therapy is a new cancer treatment modality in which a locally applied electrical field enhances cell membrane permeability, allowing greater intracellular accumulation of a chemotherapeutic agent.
  • OBJECTIVE: To evaluate the efficacy of electroporation therapy in treating basal cell and squamous cell carcinomas of the skin.
  • MATERIALS AND METHODS: Six patients with skin cancer of the head and neck were treated using electroporation therapy with intratumorally injected bleomycin.
  • Orbital growth, facial nerve proximity, or proximity to cartilage of the external meatus complicated four of these tumors.
  • RESULTS: In four of the six patients, one treatment was enough to eradicate the tumor.
  • In one patient, the tumor persisted even after a second treatment with electroporation therapy.
  • One additional recurrence was recorded 6 months after the follow-up period CONCLUSION: Electroporation therapy is a promising new cancer treatment that should be further evaluated as an alternative to surgery, especially in complicated skin cancer.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Electrochemotherapy. Head and Neck Neoplasms / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Ear Neoplasms / drug therapy. Female. Humans. Male. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Dermatol Surg. 2011 Feb;37(2):286; author reply 287 [21324036.001]
  • (PMID = 20666812.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


22. Shimizu T, Iwasa T, Koike S, Nakamura T, Kanai T, Komatsu D: [Weekly administration of paclitaxel and pirarubicine for recurrent breast cancer]. Gan To Kagaku Ryoho; 2003 Jan;30(1):105-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The therapeutic efficacy of weekly coadministration of paclitaxel (TXL) and pirarubicin (THP) on docetaxel (TXT)- and epirubicin-resistant recurrent breast cancer, adverse reactions caused by this therapy, and the possibility of ambulatory treatment using it were evaluated.
  • One cycle consisted of 20 mg/m2 of THP followed by 80 mg/m2 of TXL 4 h later, repeated three times every other week.
  • An anti-emetic drug was administered before administration of THP as short premedication.
  • Adverse reactions observed included transient facial hot flushes, alopecia grade 1 or milder grade 1 symptoms, and peripheral nerve damage.
  • Grade 3 and grade 2 neutropenia occurred in 1 and 6 patients, respectively, and 4 patients were admitted for treatment of this.
  • In conclusion, the short premedication was useful, and this was thought to make it possible to conduct ambulatory treatment with TXL + THP in some patients.
  • It will be necessary to clarify the characteristics of this therapy by administering it to a wider spectrum of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Doxorubicin / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Alopecia / chemically induced. Drug Administration Schedule. Female. Humans. Leukopenia / chemically induced. Middle Aged. Nausea / chemically induced. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12557713.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


23. Park KA, Oh SY: Nasopharyngeal carcinoma presenting with rapidly progressive severe binocular optic neuropathy and periocular pain in a young man. J Neuroophthalmol; 2010 Jun;30(2):150-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For a presumptive diagnosis of retrobulbar optic neuritis, he was treated with intravenous corticosteroids, and vision improved transiently.
  • But vision later worsened to no light perception, and MRI revealed bilateral optic nerve enhancement with dural enhancement and thickening in the anterior skull base, sella, and retroclival areas, findings initially interpreted as inflammatory.
  • Nasopharyngoscopy disclosed a soft tissue lesion filling the apex of the nasopharynx and the posterior portion of the ethmoid sinus with associated sinusitis.
  • [MeSH-major] Carcinoma / complications. Carcinoma / pathology. Facial Pain / etiology. Nasopharyngeal Neoplasms / complications. Nasopharyngeal Neoplasms / pathology. Optic Nerve Diseases / etiology
  • [MeSH-minor] Adult. Blindness / etiology. Diagnosis, Differential. Diagnostic Errors / prevention & control. Disease Progression. Drug Therapy. Dura Mater / pathology. Ethmoid Sinus / pathology. Eye / physiopathology. Humans. Magnetic Resonance Imaging. Male. Nasopharynx / pathology. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Optic Nerve / pathology. Optic Nerve / physiopathology. Sella Turcica / pathology. Skull Base Neoplasms / secondary. Sphenoid Bone / pathology. Time Factors. Vision, Low / etiology

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414132.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Phan R, Phan L, Ginsberg LE, Blumenschein G, Williams MD, Esmaeli B: Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread. Arch Ophthalmol; 2009 Aug;127(8):1074-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cranial Nerve Neoplasms / drug therapy. Facial Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Trigeminal Nerve Diseases / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Cheek. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19667357.001).
  • [ISSN] 1538-3601
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down






Advertisement